Operating profit swung to a $45.6m loss; PBT margin hit unprecedented -4.8%

Operating profit swung from +$20.4m to -$45.6m, a $66.0m deterioration, while PBT moved from -$3.3m to -$64.2m and NPAT from -$5.5m to -$51.2m. Revenue rose modestly to $1.3b from $1.3b, but a basis caveat sits on year-on-year comparability owing to segment composition changes.

The balance sheet absorbed most of the strain. Gross borrowings rose 33.9% to $197.4m, cash fell 47.9% to $30.5m, total equity dropped 10.0% to $521.9m, and NTA per share fell 12.2% to $3.61. Management commentary attributes the result to cyclone-driven volume damage, with strategy delivery delayed "at least 18 months."

NPAT margin at -3.8% (mean -0.1%) and ROE at -10.1% (mean -0.2%) are both flagged as unprecedented lows in the supplied historical baseline. This matters because the result is not a cyclical dip within a normal band; it is outside the company's recent operating range and concentrated in segments that should be its core engine.

Segment economics tell two stories. The Apples segment (60% of revenue) saw its result fall from $27.8m to $10.6m on a derived margin of 1.3% (prior 3.6%), while VentureFruit swung from an $11.0m profit on $29.1m of revenue to a $14.7m loss on $9.0m of revenue. This means the headline weather narrative coexists with a material revenue collapse in a higher-margin licensing-style segment that needs separate explanation.

Leverage moved decisively in the wrong direction. Net debt nearly doubled to $166.9m from $89.0m, gross borrowings rose by $50.0m, and equity contracted by $58.3m. With FY23 generating only $25.6m of operating cash against $68.5m of capex, the financing gap was bridged on the balance sheet rather than from earnings.

The shape data shows HY23 NPAT was -$17.7m and full-year NPAT -$51.2m, implying a roughly -$33.4m second-half loss that was worse than the first half. That weighting matters because it indicates the cyclone impact and weak pricing extended well beyond the immediate event window in February 2023.

Management's commentary points to insurance recovery being recognised in the FY23 result and an "at least 18 months" delay to the strategy. Neither the quantum of the recovery booked nor the path back to historical margin levels is quantified in the supplied context.

Capex fell 31.5% to $68.5m (5.1% of revenue, down from 7.7%), which directly relieved the cash statement, and the operating working-capital build of $42.3m is within the company's historical range (4-period mean $43.2m). Pre-lease free cash flow of -$42.9m sits at the lower edge of the historical range (mean -$4.3m).

Working-capital line items signal pressure underneath the headline. Trade debtors rose 20.6% to $167.4m on revenue up only 2.3%; debtor days of 45.8 are within Annolyse's historical range (mean 36.3 days) but elevated. Inventory days at 18.5 are above the company's recent normal range (mean 15.0 days). This matters because the cash improvement was assisted by lower capex and the receivables build has not yet converted, so the next period's working-capital reversal cannot be assumed.

This briefing cannot assess the size of the insurance recovery already booked, covenant headroom, or any FY24 guidance, because none of those items are present in the supplied release context.